204 related articles for article (PubMed ID: 32088205)
1. Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?
Howell J; Chan HLY; Feld JJ; Hellard ME; Thompson AJ
Gastroenterology; 2020 Jun; 158(8):2028-2032. PubMed ID: 32088205
[No Abstract] [Full Text] [Related]
2. Preventing infection-associated cancer: from bench to hillside.
Goedert JJ
J Natl Cancer Inst; 2005 Feb; 97(4):245-6. PubMed ID: 15713953
[No Abstract] [Full Text] [Related]
3. Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.
Stournaras E; Neokosmidis G; Stogiannou D; Protopapas A; Tziomalos K
Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1277-1282. PubMed ID: 30179906
[TBL] [Abstract][Full Text] [Related]
4. [Modern strategy in the treatment of chronic hepatitis B: progress and prospects].
Isakov VA
Eksp Klin Gastroenterol; 2007; (2):107-12. PubMed ID: 17539354
[No Abstract] [Full Text] [Related]
5. Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine.
Papatheodoridis GV; Voulgaris T; Papatheodoridi M; Kim WR
Hepatology; 2020 Dec; 72(6):2197-2205. PubMed ID: 32602980
[No Abstract] [Full Text] [Related]
6. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J.
Liu CJ; Kao JH
Semin Liver Dis; 2013 May; 33(2):97-102. PubMed ID: 23749665
[TBL] [Abstract][Full Text] [Related]
7. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of hepatitis B treatment in clinical practice.
Scaglione SJ; Lok AS
Gastroenterology; 2012 May; 142(6):1360-1368.e1. PubMed ID: 22537444
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus and hepatitis C virus dual infection.
Caccamo G; Saffioti F; Raimondo G
World J Gastroenterol; 2014 Oct; 20(40):14559-67. PubMed ID: 25356020
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
[TBL] [Abstract][Full Text] [Related]
11. Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges.
Chen CJ
Gut; 2018 Apr; 67(4):595-598. PubMed ID: 29367206
[No Abstract] [Full Text] [Related]
12. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
[TBL] [Abstract][Full Text] [Related]
13. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
[TBL] [Abstract][Full Text] [Related]
14. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase.
Lee HA; Lee HW; Kim IH; Park SY; Sinn DH; Yu JH; Seo YS; Um SH; Lee JI; Lee KS; Lee CH; Tak WY; Kweon YO; Kang W; Paik YH; Lee JW; Suh SJ; Jung YK; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Yim HJ; Kim SU
Aliment Pharmacol Ther; 2020 Jul; 52(1):196-204. PubMed ID: 32452564
[TBL] [Abstract][Full Text] [Related]
15. Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers.
Kim HS; Baatarkhuu O; Lee HW; Park JY; Kim DY; Ahn SH; Song K; Han KH; Kim BK; Kim SU
Liver Int; 2019 Jan; 39(1):81-89. PubMed ID: 30280461
[TBL] [Abstract][Full Text] [Related]
16. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
[TBL] [Abstract][Full Text] [Related]
17. Natural history of chronic hepatitis B: phases in a complex relationship.
Croagh CM; Lubel JS
World J Gastroenterol; 2014 Aug; 20(30):10395-404. PubMed ID: 25132755
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma.
Llovet JM; Lok A
J Natl Cancer Inst; 2008 Aug; 100(16):1121-3. PubMed ID: 18695130
[No Abstract] [Full Text] [Related]
19. Long-term follow-up of patients with hepatitis B e antigen negative chronic hepatitis B.
Bekku D; Arai M; Imazeki F; Yonemitsu Y; Kanda T; Fujiwara K; Fukai K; Sato K; Itoga S; Nomura F; Yokosuka O
J Gastroenterol Hepatol; 2011 Jan; 26(1):122-8. PubMed ID: 21175805
[TBL] [Abstract][Full Text] [Related]
20. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.
Okada M; Enomoto M; Kawada N; Nguyen MH
Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1095-1104. PubMed ID: 28752768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
